(Q27853117)

13 November 2016

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

neurofibromatosis type II

27 February 2020

main subject

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Olivier Sterkers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Michel Kalamarides

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Daniele Bernardeschi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Eric Raymond

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Marina Esposito-Farese

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Stéphanie Trunet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Christian Mawrin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Béatrice Larroque

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Marco Giovannini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

8 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuro-Oncology

27 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

313-320

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

Neurofibromatosis type 2.

27 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Stereotactic radiosurgery for neurofibromatosis 2-associated vestibular schwannomas: toward dose optimization for tumor control and functional outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Hearing improvement after bevacizumab in patients with neurofibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Recommendations for imaging tumor response in neurofibromatosis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

mTORC1 inhibitors suppress meningioma growth in mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Sample size tables for exact single-stage phase II designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1710-0

Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC

21 January 2018

1 reference

12 December 2020

Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab

1 reference

12 December 2020

Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates

1 reference

12 December 2020

Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation

1 reference

12 December 2020

10.1007/S11060-014-1710-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

27 February 2020

1041205376

0 references

2 references

13 November 2016

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25567352%20AND%20SRC:MED&resulttype=core&format=json